1. Home
  2. ANNX vs PRLB Comparison

ANNX vs PRLB Comparison

Compare ANNX & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANNX
  • PRLB
  • Stock Information
  • Founded
  • ANNX 2011
  • PRLB 1999
  • Country
  • ANNX United States
  • PRLB United States
  • Employees
  • ANNX N/A
  • PRLB N/A
  • Industry
  • ANNX Biotechnology: Pharmaceutical Preparations
  • PRLB Metal Fabrications
  • Sector
  • ANNX Health Care
  • PRLB Industrials
  • Exchange
  • ANNX Nasdaq
  • PRLB Nasdaq
  • Market Cap
  • ANNX 668.8M
  • PRLB 713.9M
  • IPO Year
  • ANNX 2020
  • PRLB 2012
  • Fundamental
  • Price
  • ANNX $5.14
  • PRLB $41.50
  • Analyst Decision
  • ANNX Strong Buy
  • PRLB Buy
  • Analyst Count
  • ANNX 7
  • PRLB 4
  • Target Price
  • ANNX $15.80
  • PRLB $40.33
  • AVG Volume (30 Days)
  • ANNX 1.4M
  • PRLB 379.0K
  • Earning Date
  • ANNX 11-14-2024
  • PRLB 11-01-2024
  • Dividend Yield
  • ANNX N/A
  • PRLB N/A
  • EPS Growth
  • ANNX N/A
  • PRLB N/A
  • EPS
  • ANNX N/A
  • PRLB 0.94
  • Revenue
  • ANNX N/A
  • PRLB $504,188,000.00
  • Revenue This Year
  • ANNX N/A
  • PRLB $0.88
  • Revenue Next Year
  • ANNX N/A
  • PRLB $3.03
  • P/E Ratio
  • ANNX N/A
  • PRLB $44.03
  • Revenue Growth
  • ANNX N/A
  • PRLB 1.97
  • 52 Week Low
  • ANNX $2.27
  • PRLB $25.76
  • 52 Week High
  • ANNX $8.40
  • PRLB $41.87
  • Technical
  • Relative Strength Index (RSI)
  • ANNX 20.42
  • PRLB 70.74
  • Support Level
  • ANNX $5.05
  • PRLB $36.07
  • Resistance Level
  • ANNX $7.63
  • PRLB $40.00
  • Average True Range (ATR)
  • ANNX 0.37
  • PRLB 1.63
  • MACD
  • ANNX -0.23
  • PRLB 0.17
  • Stochastic Oscillator
  • ANNX 3.68
  • PRLB 98.13

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About PRLB Proto Labs Inc. Common stock

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The majority of its revenue is derived from the United States of America.

Share on Social Networks: